At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 162 enrolled
Drug / intervention
AZD1722 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b, Randomized, Double Blind, Placebo-controlled, Parallel Group, Multicentre Dose Finding Study to Evaluate the Efficacy, Safety and Tolerability of AZD1722 to Treat Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)
In Brief
A Phase 2 clinical trial evaluating AZD1722 and Placebo for Hyperphosphatemia. Completed, enrolled 162 participants across 41 sites in 4 countries.
Detailed Summary
Randomized. double blind, placebo controlled, parallel arms dose finding study with a 4 weeks treatment period
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperphosphatemia
CountriesPoland, Slovakia, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMar 2014
First PostedMar 2014
Primary CompletionNov 2014
TodayJul 2026
First PostedMar 7, 2014
Enrollment StartMar 1, 2014
Primary CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 12.3 years ago
Interventions
AZD1722drug
AZD1722, oral tablet
Placebodrug
Placebo bid, double dummy technique